Jean George

Ms. George is a General Partner of Lightstone Ventures. She focuses on biopharmaceutical and medical device investments out of the firm’s Boston office, where she also serves as a General Partner of Advanced Technology Ventures (ATV). Her representative investments include Acceleron Pharma (NASDAQ: XLRN), Calithera Biosciences (NASDAQ: CALA), Catabasis Pharmaceuticals (NASDAQ: CATB), Flex Pharma (NASDAQ: FLKS), Five Prime Therapeutics (NASDAQ: FPRX), Gemini Therapeutics, Hydra Biosciences, Hypnion (acquired by Eli Lilly), Portola Pharmaceuticals (NASDAQ: PTLA), Proteolix (acquired by Onyx Pharmaceuticals), Thrasos Therapeutics, Tizona Therapetics, Verastem (NASDAQ: VSTM), and Zeltiq Aesthetics (NASDAQ: ZLTQ).

Ms. George has been featured on the Forbes Midas List and was previously a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. She has been in the biopharmaceutical industry for over 20 years, including 10 years with Genzyme Corporation, where she held a variety of operational roles in marketing, product development, and business development, including Vice President of Global Sales and Marketing. She also was Vice President and Founder of Genzyme’s Tissue Repair Division.

Ms. George joined BancBoston Ventures in 1998 to lead its life sciences investments. There she led investments in Neurometrix (NASDAQ: NURU), Ironwood Pharmaceuticals (NASDAQ: IRWD), NuGenesis Technologies (acquired by Waters), and Syntonix Pharmaceuticals (acquired by Biogen/Idec). Previously, Ms. George spent six years working in chemistry and bioresearch.

Ms. George has an MBA from Simmons College Graduate School of Management and a BS from the University of Maine. Her representative investments include Acceleron, Calithera, Catabasis, FivePrime, Flex Pharma, Hydra Biosciences, Hypnion, Portola, Proteolix, Thrasos Therapeutics, Tizona Therapeutics, Verastem, and ZELTIQ.